Composition for treating cancer
    1.
    发明授权
    Composition for treating cancer 失效
    用于治疗癌症的组合物

    公开(公告)号:US6071888A

    公开(公告)日:2000-06-06

    申请号:US787209

    申请日:1997-01-22

    CPC分类号: A61K31/7004

    摘要: The present invention is directed to compositions containing beta-alanine which are useful for treating cancer. The composition preferably comprises a ribose compound, L-beta-alanine, ascorbic acid, and nicotinic acid. The present invention is particularly directed to a composition useful for treating melanoma, and a method for treating melanoma with the composition.

    摘要翻译: 本发明涉及含有β-丙氨酸的组合物,其可用于治疗癌症。 组合物优选包含核糖化合物,L-β-丙氨酸,抗坏血酸和烟酸。 本发明特别涉及可用于治疗黑素瘤的组合物,以及用该组合物治疗黑素瘤的方法。

    Grafted macromolecular conjugates of doxorubicin with anticancer activity and method of their preparation
    3.
    发明授权
    Grafted macromolecular conjugates of doxorubicin with anticancer activity and method of their preparation 有权
    多柔比星的接枝大分子缀合物具有抗癌活性及其制备方法

    公开(公告)号:US08603990B2

    公开(公告)日:2013-12-10

    申请号:US12441619

    申请日:2007-09-18

    CPC分类号: A61K47/58 A61K47/65

    摘要: A polymeric drug, in which a cancerostatic connected via spacers containing hydrolytically cleavable hydrazone bonds is bound to a water-soluble polymeric carrier prepared on the basis of a N-(2-hydroxypropyl)methacrylamide copolymer, wherein the structure of the polymeric drug consists of the main chain of N-(2-hydroxypropyl)methacrylamide carrying the cancerostatic and another chain of N-(2-hydroxypropyl)methacrylamide—a graft, which may also carry a cancerostatic, said grafts being bound to the main chain by a bond that is stable in the body and/or by a bond cleavable in the body, especially by an oligopeptide spacer selected from the series of GlyLeuGly (SEQ ID. NO. 1), GlyPheGly (SEQ ID. NO. 2), GlyPheLeuGly (SEQ ID. NO. 3) and GlyLeuPheGly (SEQ ID. NO. 4), and a method of its preparation.

    摘要翻译: 一种聚合物药物,其中通过含有可水解可切割腙键的间隔物连接的癌基团与基于N-(2-羟丙基)甲基丙烯酰胺共聚物制备的水溶性聚合物载体结合,其中聚合物药物的结构由 携带癌抑制剂的N-(2-羟丙基)甲基丙烯酰胺的主链和另一个N-(2-羟丙基)甲基丙烯酰胺链 - 也可以携带癌抑制剂的移植物,所述移植物通过键连接到主链上, 特别是通过选自GlyLeuGly(SEQ ID NO:1),GlyPheGly(SEQ ID NO:2),GlyPheLeuGly(SEQ ID NO:1),GlyPheLeuGly(SEQ ID NO:1), ,3号)和GlyLeuPheGly(SEQ ID NO.4)及其制备方法。

    Method for the Preparation of Polymeric Conjugates of Doxorubicin with Ph-Controlled Release of the Drug
    4.
    发明申请
    Method for the Preparation of Polymeric Conjugates of Doxorubicin with Ph-Controlled Release of the Drug 审中-公开
    用药物控释药物多柔比星聚合物缀合物的制备方法

    公开(公告)号:US20080318879A1

    公开(公告)日:2008-12-25

    申请号:US12065745

    申请日:2006-09-05

    IPC分类号: A61K47/48 A61P35/00

    CPC分类号: A61K47/58

    摘要: A method for the preparation of polymeric conjugates of N-(2-hydroxypropyl)methacrylamide and a methacryloylaminoacylhydrazone of doxorubicin with pH-controlled release of the drug, comprising the following three steps of synthesis: a. preparation of a monomeric methacryloylaminoacylhydrazine, wherein the aminoacyl is derived from an amino acid or oligopeptide, by reaction of a methacryloyl halide with the respective peptide, amino acid, or a derivative thereof, and subsequent hydrazinolysis, b. synthesis of a polymeric precursor by direct copolymerization of N-(2-hydroxypropyl)methacrylamide with the methacryloylaminoacylhydrazine, and c. binding of doxorubicin to the polymeric precursor by reaction thereof with doxorubicin hydrochloride.

    摘要翻译: 一种制备N-(2-羟丙基)甲基丙烯酰胺和多柔比星的甲基丙烯酰氨基酰腙的聚合物共轭物的方法,其具有pH控制释放的药物,包括以下三个合成步骤:a。 b。通过甲基丙烯酰卤与相应的肽,氨基酸或其衍生物的反应以及随后的肼解,制备单体甲基丙烯酰氨基酰肼,其中氨酰基衍生自氨基酸或寡肽。 通过N-(2-羟丙基)甲基丙烯酰胺与甲基丙烯酰基氨基酰肼的直接共聚合成聚合物前体,和c。 通过与多柔比星盐酸盐的反应将多柔比星与聚合物前体结合。

    Synthetic polymeric drugs
    6.
    发明授权
    Synthetic polymeric drugs 失效
    合成高分子药物

    公开(公告)号:US5037883A

    公开(公告)日:1991-08-06

    申请号:US438352

    申请日:1989-11-17

    摘要: A polymeric drug comprising an inert synthetic polymeric carrier combined through aminoacid or peptide spacers with a bioactive molecule, a targeting moiety, and an optional cross-linkage, comprises:(a) 5.0 to 99.7 mol % of units derived from N-(2-hydroxypropyl)methacrylamide,(b) 0.2 to 20.0 mol % of units derived from an N-methylacrylcylated peptide, the peptide groups being bound to a bioactive moiety,(c) 0.1 to 94.8 mol % of units derived from N-methacrylamide, N-methacrylic acid or an N-methacrylolated aminoacid or peptide, to which are bound a determinant capable of interacting with specific receptors on cell surfaces,(d) optionally, 0 to 5 mol % of units derived from an N-methacryloylated peptide, the peptide groups being bound to a linking group which is similarly to a similar peptide group attached to another polymer chain, and(e) optionally, as a bioassay label, 0 to 2 mol % units derived from N-methyacryloylated tyrosinamide.

    摘要翻译: 包含通过氨基酸或肽间隔物与生物活性分子,靶向部分和任选的交联结合的惰性合成聚合物载体的聚合物药物包括:(a)5.0-99.7mol%衍生自N-(2- 羟丙基)甲基丙烯酰胺,(b)衍生自N-甲基丙烯酰化肽的单元的0.2〜20.0摩尔%,所述肽基团与生物活性部分结合,(c)0.1〜94.8摩尔%的来源于N-甲基丙烯酰胺,N- 甲基丙烯酸或N-甲基丙烯酰化的氨基酸或肽,其结合能够与细胞表面上的特异性受体相互作用的决定簇,(d)任选地0至5摩尔%的衍生自N-甲基丙烯酰基化肽的单元,所述肽基团 与类似于连接于另一聚合物链的肽基团的连接基团结合,和(e)任选地,作为生物测定标记物,衍生自N-甲基丙烯酰基化酪氨酰胺的0至2摩尔%的单位。

    Dendritic High-molecular-weight Polymer Drug Carriers and Their Conjugates with Drugs Especially for Treatment of Solid Tumours
    7.
    发明申请
    Dendritic High-molecular-weight Polymer Drug Carriers and Their Conjugates with Drugs Especially for Treatment of Solid Tumours 有权
    树突状高分子量聚合物药物载体及其与药物的共轭物特别用于治疗实体瘤

    公开(公告)号:US20120296048A1

    公开(公告)日:2012-11-22

    申请号:US13516607

    申请日:2010-12-14

    IPC分类号: C08F20/56

    摘要: The present invention relates to water-soluble high-molecular-weight polymer drug carriers and their conjugates with drugs, derived from dendrimers of the amidoamine and 2,2-bis(hydroxymethyl)propanoic types, the amino and hydroxy end groups of which are attached to semitelechelic copolymers of N-(2 hydroxypropyl)methacrylamide (HPMA) through biodegradable spacers. The polymer carriers and conjugates enable targeted transport notably of anticancer drugs into solid tumors in which biodegradation, the associated controlled drug release and subsequent elimination of polymer carrier from the organism are provided. The polymer carrier conjugated with a cancerostatic for use in targeted therapy of human tumors.

    摘要翻译: 本发明涉及水溶性高分子量聚合物药物载体及其与药物的共轭物,其衍生自酰氨基胺的树枝状大分子和2,2-双(羟甲基)丙酸类型,其氨基和羟基端基连接 通过可生物降解的间隔物将N-(2羟丙基)甲基丙烯酰胺(HPMA)的半触变共聚物。 聚合物载体和共轭物使得能够将抗癌药物靶向运输到实体瘤中,其中提供生物降解,相关的受控药物释放和随后从生物体中消除聚合物载体。 与用于靶向治疗人类肿瘤的癌症药物结合的聚合物载体。

    PH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy
    8.
    发明授权
    PH-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy 有权
    用于靶向治疗的蒽环类抗癌药物的PH敏感性聚合物缀合物

    公开(公告)号:US07919076B2

    公开(公告)日:2011-04-05

    申请号:US10499422

    申请日:2002-12-20

    IPC分类号: A61K31/74

    CPC分类号: A61K47/6883 A61K47/65

    摘要: Conjugates consisting of a polymeric carrier constituted by 30 to 3,000 monomer units linked to form a polymeric chain, composed of a) 60 to 99% of N-(2-hydroxypropyl)methacrylamide units, b) 1 to 25% of units of methacryloylated hydrazones of α-amino acids, ε-amino acids, aromatic amino acids or oligopeptides terminated with a molecule of an anthracycline cancerostatic, c) 0.5 to 15% of units of methacryloylated α-amino acids, ε-amino acids, aromatic amino acids or oligopeptides or their sodium salts.

    摘要翻译: 由聚合物载体构成的共轭体由连接形成聚合物链的30至3,000个单体单元构成,由a)60至99%的N-(2-羟丙基)甲基丙烯酰胺单元组成,b)1至25%的甲基丙烯酰化腙单元 α-氨基酸,α-氨基酸,芳香族氨基酸或用蒽环类抗癌药物分子终止的寡肽,c)0.5〜15%的甲基丙烯酰化α-氨基酸单元,氨基酸,芳香族氨基酸 或寡肽或其钠盐。

    GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION
    9.
    发明申请
    GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION 有权
    具有抗肿瘤活性的多菌灵的接枝大分子结合及其制备方法

    公开(公告)号:US20090306004A1

    公开(公告)日:2009-12-10

    申请号:US12441619

    申请日:2007-09-18

    CPC分类号: A61K47/58 A61K47/65

    摘要: A polymeric drug, in which a cancerostatic connected via spacers containing hydrolytically cleavable hydrazone bonds is bound to a water-soluble polymeric carrier prepared on the basis of a N-(2-hydroxypropyl)methacrylamide copolymer, wherein the structure of the polymeric drug consists of the main chain of N-(2-hydroxypropyl)methacrylamide carrying the cancerostatic and another chain of N-(2-hydroxypropyl)methacrylamide—a graft, which may also carry a cancerostatic, said grafts being bound to the main chain by a bond that is stable in the body and/or by a bond cleavable in the body, especially by an oligopeptide spacer selected from the series of GlyLeuGly, GlyPheGly, GlyPheLeuGly and GlyLeuPheGly, and a method of its preparation.

    摘要翻译: 一种聚合物药物,其中通过含有可水解可切割腙键的间隔物连接的癌基团与基于N-(2-羟丙基)甲基丙烯酰胺共聚物制备的水溶性聚合物载体结合,其中聚合物药物的结构由 携带癌抑制剂的N-(2-羟丙基)甲基丙烯酰胺的主链和另一个N-(2-羟丙基)甲基丙烯酰胺链 - 也可以携带癌抑制剂的移植物,所述移植物通过键连接到主链上, 特别是通过选自GlyLeuGly,GlyPheGly,GlyPheLeuGly和GlyLeuPheGly的寡肽隔离物及其制备方法,在体内和/或可通过体内可切割的键稳定。

    Ph-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy
    10.
    发明申请
    Ph-sensitive polymeric conjugates of an anthracycline cancerostatic drug for targeted therapy 有权
    用于靶向治疗的蒽环类抗癌药物的敏感性聚合物缀合物

    公开(公告)号:US20060057099A1

    公开(公告)日:2006-03-16

    申请号:US10499422

    申请日:2002-12-20

    CPC分类号: A61K47/6883 A61K47/65

    摘要: Conjugates consisting of a polymeric carrier constituted by 30 to 3,000 monomer units linked to form a polymeric chain, composed of a) 60 to 99% of N-(2-hydroxypropyl)methacrylamide units, b) 1 to 25% of units of methacryloylated hydrazones of α-amino acids, ε-amino acids, aromatic amino acids or oligopeptides terminated with a molecule of an anthracycline cancerostatic, c) 0.5 to 15% of units of methacryloylated α-amino acids, ε-amino acids, aromatic amino acids or oligopeptides or their sodium salts.

    摘要翻译: 由聚合物载体构成的共轭体由连接形成聚合物链的30至3,000个单体单元构成,由a)60至99%的N-(2-羟丙基)甲基丙烯酰胺单元组成,b)1至25%的甲基丙烯酰化腙单元 α-氨基酸,ε-氨基酸,芳族氨基酸或用蒽环类抗癌药物分子终止的寡肽,c)0.5至15%的甲基丙烯酰化α-氨基酸,ε-氨基酸,芳族氨基酸或寡肽的单位 或其钠盐。